Skip to main content
Premium Trial:

Request an Annual Quote

TGen and Kronos to Study 570K SNPs in Alzheimer s Research

NEW YORK, Feb. 24 (GenomeWeb News) - The Translational Genomics Research Institute and Kronos Science Laboratories will cooperate in an Alzheimer's research study, the institute said yesterday.


The 18-month study is expected to cost approximately $6 million and will be jointly funded by TGen and Kronos, a subsidiary of Kronos Optimal Health. Both are located in Phoenix.


In the study, researchers will examine some 570,000 SNPs from deceased individuals who were confirmed to have Alzheimer's disease at autopsy, and another 1,000 dead who were confirmed to be free of the disease at autopsy. DNA samples will be obtained from brain banks in the USand Europe.


Kronos will have an exclusive worldwide license to all intellectual property that results from the research, and will look to develop a diagnostic for genetic predisposition.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more